TL;DR When standard chemotherapy fails in stage 4 colorectal cancer, targeted therapies like EGFR inhibitors (cetuximab, panitumumab) and anti-angiogenesis drugs (bevacizumab, regorafenib) offer alternative pathways based on molecular testing [1] [3] . Dr. Bharat Patodiya comprehensive molecular profiling identifies specific genetic mutations (KRAS, BRAF, MSI status) that determine eligibility for advanced treatment options including immunotherapy and kinase inhibitors. Emerg